BARTÁKOVÁ, Vendula, Veronika TANHÄUSEROVÁ, Lukáš PÁCAL, Katarína KURICOVÁ, Petra LINHARTOVÁ and Kateřina KAŇKOVÁ. Diabetic nephropathy - Pharmacogenomics and variability in genes of renin-angiotensin-aledosterone system. In XV. Setkání biochemiků a molekulárních biologů. Brno: Masarykova univerzita. 2011. ISBN 978-80-210-5594-0.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Diabetic nephropathy - Pharmacogenomics and variability in genes of renin-angiotensin-aledosterone system
Name in Czech Diabetická nefropatie - farmakogenomika a variablita v genech renin-angiotensin-aldosteronového systému
Authors BARTÁKOVÁ, Vendula, Veronika TANHÄUSEROVÁ, Lukáš PÁCAL, Katarína KURICOVÁ, Petra LINHARTOVÁ and Kateřina KAŇKOVÁ.
Edition XV. Setkání biochemiků a molekulárních biologů. Brno: Masarykova univerzita, 2011.
Other information
Original language English
Type of outcome Conference abstract
Field of Study Genetics and molecular biology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Organization unit Faculty of Medicine
ISBN 978-80-210-5594-0
Keywords (in Czech) diabetes mellitus, diabetická nefropatie, renin-angiotenzin-aldosteronový systém, farmakogenomika
Keywords in English diabetes mellitus, diabetic nephropathy, renin-angiotenzin-aldosterone system, pharmacogenomics
Changed by Changed by: MUDr. Vendula Bartáková, Ph.D., učo 141885. Changed: 2/11/2011 09:38.
Abstract
Diabetic nephropathy (DN) is one of the most common and serious complications of diabetes mellitus with pathological activation of renin-angiotensin-aldosterone system (RAAS) as the key pathogenetic mechanism. Pharmacological blockade of RAAS represents the main renoprotective treatment of DN. Several single nucleotide polymorphisms (SNPs) were shown to influence interindividual variability of RAAS (e.g circulating levels of RAAS compounds and enzyme activities). These functional genetic variants are supposed to modify therapeutic effect of RAAS blockers. Genetic variability together with other factors, which are objects of therapeutical compensation (e.g. glycaemia, blood pressure, proteinuria, lipidaemia and body weight) can affect progression of kidney damage in diabetics. The aim of this project is to study the effect of genetic variability in the selected components of RAAS in the progression of kidney disease by diabetic patients. Three SNPs in angiotensin converting enzyme (ACE - rs4343), angiotensinogen (ATG M235T - rs699) and angiotensin II type I receptor gene (ATR1 A1166C - rs5186) were genotyped using restriction fragment length polymorphism PCR. This case – case study involved 433 patients with a different degree of DN. Results of the haplotype analysis will be compared with a pharmacological treatment - especially RAAS blockers. We expect a variability of haplotypes in RAAS genes among patients with different degree of DN and a possibility of an implementation of phamacogenomic approach to the treatment of DN.
Links
NT11405, research and development projectName: Mikrobiologické a genetické determinanty rozvoje a progrese parodontitidy u diabetiků 1. a 2. typu a jejich reciproční vztah ke kompenzaci diabetu
Investor: Ministry of Health of the CR
PrintDisplayed: 26/7/2024 00:24